Online citations, reference lists, and bibliographies.
← Back to Search

A Randomized, Double-blind Trial Comparing Combinations Of Nevirapine, Didanosine, And Zidovudine For HIV-infected Patients: The INCAS Trial

J. Montaner, P. Reiss, D. Cooper, S. Vella, M. Harris, B. Conway, M. Wainberg, Richard H. Smith, P. Robinson, D. Hall, M. Myers, J. Lange
Published 1998 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Context.—Current guidelines recommend that individuals infected with the human immunodeficiency virus type 1 (HIV-1) be treated using combinations of antiretroviral agents to achieve sustained suppression of viral replication as measured by the plasma HIV-1 RNA assay, in the hopes of achieving prolonged remission of the disease. However, until recently, many drug combinations have not led to sustained suppression of HIV-1 RNA.Objective.—To compare the virologic effects of various combinations of nevirapine, didanosine, and zidovudine.Design.—Double-blind, controlled, randomized trial.Setting.—University-affiliated ambulatory research clinics in Italy, the Netherlands, Canada, and Australia (INCAS).Patients.—Antiretroviral therapy–naive adults free of the acquired immunodeficiency syndrome with CD4 cell counts between 0.20 and 0.60×109/L (200-600/µL).Intervention.—Patients received zidovudine plus nevirapine (plus didanosine placebo), zidovudine plus didanosine (plus nevirapine placebo), or zidovudine plus didanosine plus nevirapine.Main Outcome Measure.—Plasma HIV-1 RNA.Results.—Of the 153 enrolled patients, 151 were evaluable. At week 8, plasma HIV-1 RNA levels had decreased by log 2.18, 1.55, and 0.90 in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, respectively (P<.05). The proportions of patients with plasma HIV-1 RNA levels below 20 copies per milliliter at week 52 were 51%, 12%, and 0% in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, respectively (P<.001). Viral amplification was attempted in 59 patients at 6 months. Viral isolation was unsuccessful in 19 (79%) of 24, 10 (53%) of 19, and 5 (31%) of 16 patients in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, respectively. Among patients from whom virus could be amplified, resistance to nevirapine was found in all 11 patients receiving zidovudine plus nevirapine and in all 5 patients receiving triple drug therapy. Rates of disease progression or death were 23% (11/47), 25% (13/53), and 12% (6/51) for the zidovudine plus nevirapine, zidovudine plus didanosine, and triple drug therapy groups, respectively (P=.08).Conclusions.—Triple drug therapy with zidovudine, didanosine, and nevirapine led to a substantially greater and sustained decrease in plasma viral load than the 2-drug regimens studied. Our results also suggest that suppression of viral replication, as demonstrated by a decrease in the plasma HIV-1 RNA load below the level of quantitation of the most sensitive test available, may at least forestall the development of resistance.
This paper references
10.1016/0166-0934(88)90134-6
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.
R. Pauwels (1988)
10.1126/SCIENCE.1701568
Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor.
V. Merluzzi (1990)
10.1093/INFDIS/163.5.966
Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587.
R. Koup (1991)
hibition of human immunodeficiency virus type 1 ( HIV - 1 ) by the dipyridodiazepinone BI - RG - 587
SH Cheeseman (1991)
10.1128/AAC.37.2.178
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans
S. Cheeseman (1993)
10.1128/AAC.38.1.23
Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
P. Kellam (1994)
10.1093/INFDIS/169.6.1346
Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
M. D. de Jong (1994)
10.1128/jvi.68.3.1660-1666.1994
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
D. Richman (1994)
10.1128/jcm.32.2.292-300.1994
Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection
J. Mulder (1994)
Recombinant virus assay:arapid,phenotypicassayforassessmentofdrug susceptibility of human immunodeficiency virus
P Kellam (1994)
10.1093/INFDIS/172.5.1379
A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of > 500/mm3: AIDS Clinical Trials Group Protocol 208.
D. Havlir (1995)
10.1074/JBC.270.52.31046
Effects of Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 in Cell-free Recombinant Reverse Transcriptase Assays (*)
Z. Gu (1995)
10.1093/INFDIS/171.3.537
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.
D. Havlir (1995)
10.1056/NEJM199610103351502
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
D. Katzenstein (1996)
10.1097/00002030-199606000-00009
A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV‐infected patients
A. Carr (1996)
10.1001/JAMA.276.2.146
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.
C. Carpenter (1996)
10.1093/INFDIS/174.4.713
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
K. Luzuriaga (1996)
10.1016/S0140-6736(96)05387-1
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
J. Darbyshire (1996)
10.1001/JAMA.1996.03540020068031
Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel
C. Carpenter (1996)
10.7326/0003-4819-124-12-199606150-00001
Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection
Richard D'Aquila (1996)
10.1056/NEJM199610103351501
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
S. Hammer (1996)
domized trial of addition of lamivudine plus loviride to zidovudine - containing regimens for patients with advanced HIV - 1 infection : the CAESAR trial
D Cooper (1996)
deJong MD, et al, for the DutchItalian-Australian Nevirapine Study Group. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenemic HIV-infected patients
A Carr (1996)
10.1001/JAMA.280.1.78
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
C. Carpenter (1997)
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial
E.D.M.B. Kroon (1997)
10.1016/S0140-6736(05)62289-1
Emerging international consensus for use of antiretroviral therapy
J. Montaner (1997)
10.1128/jcm.35.5.1278-1280.1997
A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity
J. Mulder (1997)
Can HIV-1 RNA viral load be used as a surrogate marker for clinical endpoints in HIV disease?
A. Babiker (1997)
10.1056/NEJM199709113371101
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
S. Hammer (1997)
10.1086/514002
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
M. D. de Jong (1997)
P, and the CAESAR Coordinating Committee. Randomized trial of addition of lamivudine plus loviride to zidovudine-containing regimens for patients with advanced HIV-1 infection: the CAESAR trial
D Cooper (1997)
Predictors of duration of plasma viral load suppression
JSG Montaner (1997)
Delta Coordinating Committee and Virology Group. Can HIV-1 RNA viral load be used as a surrogate for clinical endpoints in HIV disease
A Babiker (1997)
10.1097/00002030-199805000-00003
The effects of lamivudine treatment on HIV‐1 disease progression are highly correlated with plasma HIV‐1 RNA and CD4 cell count
J. Montaner (1998)
AVANTI 2 : a randomized , double blind , comparative trial to evaluate combination antiretroviral regimensforthetreatmentofHIV - 1 infection : AZT / 3 TC / indinavir in antiretroviral naive patients
F Goebel
AVANTI 3 : a randomized , double blind , comparative trial to evaluate the efficacy , safety and tolerance of AZT / 3 TC vs AZT / 3 TC / nelfinavir in anti - retroviral naive patients
N Clumenck
dictors of duration of plasma viral load suppression
Montaner JSG



This paper is referenced by
10.1186/s12981-020-00316-w
A comparison between different anti-retroviral therapy regimes on soluble inflammation markers: a pilot study
M. Maritati (2020)
10.1007/978-3-030-36966-8_1
Prevention of HIV Infection
I. Fong (2020)
10.1016/j.coph.2020.10.009
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens.
Murugesan Vanangamudi (2020)
10.1016/S2352-3018(19)30400-X
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
A. Phillips (2020)
10.4236/WJA.2019.92006
Evaluation of Adherence to Nevirapine for Prevention of Mother-to-Child Transmission amongst Infants of HIV Positive Mothers in the First 6 Weeks of Life in Lagos Nigeria
O. Nwaiwu (2019)
10.1007/978-981-13-8719-7_1
Allostery in Drug Development.
Xi Cheng (2019)
10.1080/17425255.2019.1673367
Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment
Yali Wang (2019)
10.1021/acs.jmedchem.8b00843
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
Vigneshwaran Namasivayam (2019)
10.1080/10511482.2018.1530274
Interdisciplinary, Community, and Peer Leadership Approach to Addressing Housing Among People Living With HIV in the Rural South
Safiya George Dalmida (2019)
10.1016/j.ijid.2019.01.017
Incomplete functional T-cell reconstitution in immunological non-responders at one year after initiation of antiretroviral therapy possibly predisposes them to infectious diseases.
Ashwini Shete (2019)
10.11604/pamj.2019.32.10.7508
Adherence to combined Antiretroviral therapy (cART) among people living with HIV/AIDS in a Tertiary Hospital in Ilorin, Nigeria
C. Anyaike (2019)
10.1186/s40360-018-0252-z
Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
J. Olalla (2018)
10.2174/1389450120666190214144609
Antiretroviral Therapy-associated Adverse Drug Reactions and their Effects on Virologic Failure- A Retrospective Cohort Study in Nigeria
I. Abah (2018)
10.1016/S0140-6736(18)30008-4
Combination ART: are two drugs as good as three?
M. Boyd (2018)
10.1080/14656566.2018.1450866
Next generation fixed dose combination pharmacotherapies for treating HIV
Margaret R Caplan (2018)
10.1016/j.cmi.2017.06.014
Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996-2016.
G. Rocheleau (2018)
10.1016/j.cnur.2018.01.008
The Psychosocial and Clinical Well-Being of Women Living with Human Immunodeficiency Virus/AIDS.
Safiya George Dalmida (2018)
10.1002/jia2.25193
Bioinformatic data processing pipelines in support of next‐generation sequencing‐based HIV drug resistance testing: the Winnipeg Consensus
Hezhao Ji (2018)
Putative HIV-1 reverse transcriptase inhibitors: design, synthesis, in vitro evaluation and in silico analysis.
Preantha. Poonan (2018)
10.1186/s12879-018-3198-2
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015
E. Quiros-Roldan (2018)
10.1186/s12977-018-0395-4
HIV evolution and diversity in ART-treated patients
G. V. van Zyl (2018)
10.1016/j.aca.2018.02.039
A competitive lateral flow assay for the detection of tenofovir.
G. W. Pratt (2018)
10.21767/2171-6625.1000251
Is the History of Substance Abuse Correlated with Neuropsychiatric Disorders and Co-morbid HIV Infection? An Urban Population Study.
R. Bassey (2018)
10.1007/s10943-017-0377-1
Examination of the Role of Religious and Psychosocial Factors in HIV Medication Adherence Rates
S. G. Dalmida (2017)
10.1063/1.4990365
Mathematical modeling of tetrahydroimidazole benzodiazepine-1-one derivatives as an anti HIV agent
Lokendra Kumar Ojha (2017)
10.7448/IAS.20.1.21941
A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996-2015
M. Olding (2017)
10.1016/B978-0-12-802101-9.00039-9
Chapter 39 – Governmental Support of Research
S. Vermund (2017)
10.1007/s11538-017-0345-7
Short-Term Antiretroviral Treatment Recommendations Based on Sensitivity Analysis of a Mathematical Model for HIV Infection of CD4+T Cells
Ana-Maria Croicu (2017)
Latency reversing agents affect HIV RNA splicing
Talia M. Mota (2017)
10.1016/j.virusres.2016.12.008
Promises and pitfalls of Illumina sequencing for HIV resistance genotyping.
C. Brumme (2017)
10.1186/s12885-017-3229-1
Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development
C. Chiu (2017)
10.1016/S0140-6736(17)31962-1
Long-acting injectable ART: next revolution in HIV?
M. Boyd (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar